BioArctic

BioArctic Financial Leverage

The Financial Leverage (Equity Multiplier) of BioArctic (BIOA B.ST) as of Oct 6, 2026 is 1.31. In the previous year, Financial Leverage (Equity Multiplier) was 1.24 — a change of 5.39% (higher).

Financial Leverage

1.31

YoY

5.39%

Last updated:

Financial Leverage (Equity Multiplier) of BioArctic is 2026 1.31 . Financial Leverage (Equity Multiplier) of BioArctic was 2025 1.24 . It decreases by 5.39% higher compared to the previous year.

The BioArctic Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.37 SEK
Jan 1, 2019
1.21 SEK
Jan 1, 2020
1.16 SEK
Jan 1, 2021
1.14 SEK
Jan 1, 2022
1.09 SEK
Jan 1, 2023
1.13 SEK
Jan 1, 2024
1.24 SEK
Jan 1, 2025
1.31 SEK
The BioArctic Financial Leverage history
YEARFinancial LeverageYoY
1.31+5.39%
1.24+9.61%
1.13+3.81%
1.09-4.10%
1.14-1.67%
1.16-4.67%
1.21-11.29%
1.37-23.65%
1.79-84.61%
11.65+862.30%
1.21—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Financial Leverage (Equity Multiplier) of BioArctic is 1.31 in 2026.

Financial Leverage (Equity Multiplier) of BioArctic changed from 1.24 to 1.31, representing a 5.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) BioArctic since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — BioArctic

All Key Metrics — BioArctic